Nifty
Sensex
:
:
12968.95
44149.72
-18.05 (-0.14%)
-110.02 (-0.25%)

Pharmaceuticals & Drugs - Global

Rating :
69/99

BSE: 539268 | NSE: SYNGENE

577.95
27-Nov-2020
  • Open
  • High
  • Low
  • Previous Close
  •  571.70
  •  587.80
  •  563.85
  •  566.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1795003
  •  10378.48
  •  596.70
  •  212.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 23,116.00
  • 65.28
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 23,520.10
  • N/A
  • 9.39

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.61%
  • 0.52%
  • 6.32%
  • FII
  • DII
  • Others
  • 14.58%
  • 5.62%
  • 2.35%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.11
  • 12.69
  • 12.23

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.07
  • 9.62
  • 9.09

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 30.69
  • 11.31
  • 10.50

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 35.78
  • 37.11

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 5.05
  • 6.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 16.28
  • 22.11

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
519.60
464.60
11.84%
421.60
420.90
0.17%
607.30
533.90
13.75%
519.10
467.10
11.13%
Expenses
370.70
328.60
12.81%
297.10
299.80
-0.90%
403.20
373.90
7.84%
375.80
326.90
14.96%
EBITDA
148.90
136.00
9.49%
124.50
121.10
2.81%
204.10
160.00
27.56%
143.30
140.20
2.21%
EBIDTM
28.66%
29.27%
29.53%
28.77%
14.01%
14.01%
27.61%
30.02%
Other Income
20.60
23.80
-13.45%
15.30
20.50
-25.37%
20.50
20.80
-1.44%
30.20
17.70
70.62%
Interest
6.60
8.40
-21.43%
7.40
7.10
4.23%
9.30
8.00
16.25%
9.80
8.20
19.51%
Depreciation
68.70
52.60
30.61%
66.10
47.40
39.45%
62.30
44.10
41.27%
57.00
42.90
32.87%
PBT
94.20
170.10
-44.62%
66.30
87.10
-23.88%
153.00
128.70
18.88%
106.70
106.80
-0.09%
Tax
10.10
42.00
-75.95%
8.30
15.10
-45.03%
32.80
28.60
14.69%
14.90
19.80
-24.75%
PAT
84.10
128.10
-34.35%
58.00
72.00
-19.44%
120.20
100.10
20.08%
91.80
87.00
5.52%
PATM
16.19%
27.57%
13.76%
17.11%
7.11%
7.11%
17.68%
18.63%
EPS
2.10
3.20
-34.38%
1.45
1.80
-19.44%
3.00
2.50
20.00%
2.29
2.17
5.53%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 20
Mar 19
Mar 18
Net Sales
2,067.60
2,011.90
1,825.60
1,423.10
Net Sales Growth
9.60%
10.20%
28.28%
 
Cost Of Goods Sold
5,006.00
519.40
531.30
381.70
Gross Profit
-2,938.40
1,492.50
1,294.30
1,041.40
GP Margin
-142.12%
74.18%
70.90%
73.18%
Total Expenditure
1,446.80
1,408.50
1,289.90
1,032.60
Power & Fuel Cost
-
45.80
41.30
34.70
% Of Sales
-
2.28%
2.26%
2.44%
Employee Cost
-
580.40
472.70
379.60
% Of Sales
-
28.85%
25.89%
26.67%
Manufacturing Exp.
-
103.70
85.70
66.70
% Of Sales
-
5.15%
4.69%
4.69%
General & Admin Exp.
-
131.60
137.40
139.30
% Of Sales
-
6.54%
7.53%
9.79%
Selling & Distn. Exp.
-
11.10
7.70
6.10
% Of Sales
-
0.55%
0.42%
0.43%
Miscellaneous Exp.
-
16.50
13.80
24.50
% Of Sales
-
0.82%
0.76%
1.72%
EBITDA
620.80
603.40
535.70
390.50
EBITDA Margin
30.03%
29.99%
29.34%
27.44%
Other Income
86.60
96.10
76.20
136.10
Interest
33.10
34.60
32.30
22.70
Depreciation
254.10
219.30
164.20
131.40
PBT
420.20
445.60
415.40
372.50
Tax
66.10
104.80
83.80
67.10
Tax Rate
15.73%
20.27%
20.17%
18.01%
PAT
354.10
412.10
331.60
305.40
PAT before Minority Interest
354.10
412.10
331.60
305.40
Minority Interest
0.00
0.00
0.00
0.00
PAT Margin
17.13%
20.48%
18.16%
21.46%
PAT Growth
-8.55%
24.28%
8.58%
 
EPS
8.85
10.30
8.29
7.64

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Shareholder's Funds
2,175.80
1,968.40
1,720.40
Share Capital
400.00
200.00
200.00
Total Reserves
1,736.90
1,740.40
1,492.20
Non-Current Liabilities
325.20
515.00
612.60
Secured Loans
0.00
346.60
568.80
Unsecured Loans
0.00
0.00
16.70
Long Term Provisions
40.90
37.40
29.00
Current Liabilities
1,539.20
1,128.60
783.60
Trade Payables
222.00
223.50
203.50
Other Current Liabilities
955.10
677.60
475.70
Short Term Borrowings
308.90
190.70
78.10
Short Term Provisions
53.20
36.80
26.30
Total Liabilities
4,040.20
3,612.00
3,116.60
Net Block
1,983.70
1,336.80
1,030.40
Gross Block
2,967.40
2,121.20
1,660.70
Accumulated Depreciation
983.70
784.40
630.30
Non Current Assets
2,427.60
1,847.90
1,396.40
Capital Work in Progress
234.10
273.70
155.40
Non Current Investment
74.00
40.00
0.00
Long Term Loans & Adv.
107.80
121.90
94.90
Other Non Current Assets
28.00
75.50
115.70
Current Assets
1,612.60
1,764.10
1,720.20
Current Investments
738.40
716.00
157.70
Inventories
25.20
43.40
86.00
Sundry Debtors
398.20
338.70
266.80
Cash & Bank
281.50
436.90
967.40
Other Current Assets
169.30
225.20
236.40
Short Term Loans & Adv.
17.80
3.90
5.90
Net Current Assets
73.40
635.50
936.60
Total Assets
4,040.20
3,612.00
3,116.60

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Cash From Operating Activity
677.10
630.40
446.20
PBT
412.10
331.60
305.40
Adjustment
328.00
212.80
248.20
Changes in Working Capital
44.10
182.10
-26.60
Cash after chg. in Working capital
784.20
726.50
527.00
Interest Paid
0.00
0.00
0.00
Tax Paid
-107.10
-96.10
-80.80
Other Direct Exp. Paid
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
Cash From Investing Activity
-428.40
-646.50
-349.30
Net Fixed Assets
-806.60
-578.80
Net Investments
-56.40
-598.30
Others
434.60
530.60
Cash from Financing Activity
-225.50
-72.40
-78.70
Net Cash Inflow / Outflow
23.20
-88.50
18.20
Opening Cash & Equivalents
165.20
252.70
234.50
Closing Cash & Equivalent
193.00
165.20
252.70

Financial Ratios

Standalone /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Book Value (Rs.)
53.42
48.51
42.30
ROA
10.77%
9.86%
9.80%
ROE
20.21%
18.26%
18.05%
ROCE
19.60%
16.98%
15.76%
Fixed Asset Turnover
0.79
0.97
0.86
Receivable days
66.84
60.53
68.43
Inventory Days
6.22
12.94
22.06
Payable days
54.25
59.30
72.96
Cash Conversion Cycle
18.82
14.17
17.52
Total Debt/Equity
0.32
0.41
0.47
Interest Cover
15.94
13.86
17.41

News Update:


  • Syngene International inks pact with Deerfield Discovery and Development Corporation
    20th Nov 2020, 09:04 AM

    The agreement aims to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation

    Read More
  • Syngene International, HiMedia get ICMR’s nod for COVID-19 antibody test kit ‘ELISafe 19’
    10th Sep 2020, 11:55 AM

    The ELISafe 19 antibody test kit has a sensitivity of 100% and specificity of 99%

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.